glp 1 agonist classification Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Understanding incretin-based therapies made simple
Description
( 10.1111/1753-0407.12644) [DOI] [PubMed] [Google Scholar] Chai W Dong Z Wang N Wang W Tao L Cao W & Liu Z
They have developed an antibody (a more complex molecule than a peptide) that antagonizes GIP
A high AUC alone does not equate to a translatable clinical tool
The goal of semaglutide therapy is not just to weigh less
Lillys research pipeline thus goes beyond tirzepatide
